Originally published on The Daily Flare.
Hearing technology is advancing faster than at any point in history, from AI-powered hearing aids to Auracast broadcast audio and the first FDA-approved gene therapy.
Hearing loss is one of the most widespread health conditions on the planet. The World Health Organization estimates that over 1.5 billion people live with some degree of hearing loss, and around 430 million of them — including 34 million children — have disabling hearing loss that requires rehabilitation. By 2050, WHO projects those figures will reach nearly 2.5 billion and more than 700 million respectively. For decades, the devices meant to help barely kept up: bulky, expensive, and stigmatized. That is changing now, and the pace of change is remarkable.
The gap between need and help has always been the story. In the United States, about 28.8 million adults could benefit from hearing aids, yet fewer than one in five uses one. Cost was a major wall: traditional prescription hearing aids average roughly $4,600 per pair in the US. What broke that wall open was a series of advances across four fronts — smarter chips, over-the-counter access, broadcast audio, and now gene therapy — that are turning hearing devices from passive amplifiers into connected, intelligent health tools.
The device landscape in 2026
| Type | Typical cost | Key advance in 2026 | Best suited for |
|---|---|---|---|
| OTC hearing aids | $200–$800 | AI speech enhancement + Auracast (e.g., Elehear Beyond 2 Pro, $799) | Mild-to-moderate loss, no prescription |
| Prescription hearing aids | ~$4,600/pair (US avg) | Multi-DNN chips, 51–56 hour batteries (Starkey Omega AI+, Phonak EON) | Moderate-to-severe loss |
| Consumer earbuds with hearing-aid software | $250–$549 | FDA-cleared OTC software (AirPods Pro 2/3, Galaxy Buds) | Mild-to-moderate loss, phone-ecosystem users |
| Cochlear implants / sound processors | Varies (implanted) | Bluetooth LE Audio + Auracast (Cochlear Osia 3, FDA clearance July 2026) | Severe-to-profound loss |
| Gene therapy | n/a (clinical) | First FDA approval (Otarmeni, April 2026) | OTOF-mutation genetic hearing loss |
How hearing technology learned to think
The biggest technical shift of this decade is neural-network sound processing running directly on the chip inside the hearing aid. Until recently, hearing aids were essentially very good amplifiers with noise filters. By 2026, all five of the major manufacturers — Sonova (Phonak), Demant (Oticon), WS Audiology (Signia), GN (ReSound), and Starkey — have moved to neural-network-driven real-time sound processing as their core approach.
Phonak led this wave with the Infinio Sphere in 2024, built around a dedicated deep neural network chip called DEEPSONIC that separates speech from background noise before anything is amplified. Then, in October 2025, the company retrained that system through the Infinio Ultra firmware update — not new hardware, just new software — on eighteen times more real-world sound scenarios, with 24 percent more precise environment detection and up to 56 hours of battery life per charge. A hearing aid that gets smarter overnight through a software update was a novelty; in 2026 it is becoming the norm.
Starkey's Omega AI+, launched in the autumn of 2026, pushed the idea further. Its G4 Gen AI Neuro Processor runs four deep neural networks simultaneously — one each for speech isolation, noise suppression, spatial and directional sound, and environment classification — alongside continuous Edge Mode, fall detection, and sleep-quality tracking, with around 51 hours of battery life per charge.
Phonak answered with the EON, also in 2026, built on the HYPERSONIC chip with Spheric Speech Clarity 3.0 for deep neural network speech-and-noise separation, AutoSense OS AI 8.0, and WindBlock 2.0, which cuts wind noise by up to 50 dB and improves signal-to-noise ratio by up to 30 dB. It combines Bluetooth Classic, Roger Direct, and Auracast in one device, and it won the 2026 Hearing Technology Innovator Award.
Milestones on the road here
2022 — the OTC rule lowers the wall. The FDA's final rule creating the over-the-counter hearing aid category was published on August 17, 2022 and took effect on October 17, 2022. For the first time, adults 18 and older with perceived mild-to-moderate hearing loss could buy air-conduction devices with no prescription, no medical exam, and no audiologist fitting. A 2025 MarkeTrak industry survey found that hearing-device adoption among US adults with perceived hearing difficulty reached 39 percent, with OTC devices contributing 5.7 percentage points — and 70 percent of first-time buyers chose OTC.
2024 — earbuds become hearing aids. On September 12, 2024, the FDA authorized Apple's Hearing Aid Feature for AirPods Pro 2 — the first over-the-counter hearing-aid software device. A five-minute hearing test on an iPhone creates a personal audiogram, and the AirPods then apply real-time personalized amplification for mild-to-moderate hearing loss. In August 2026, Samsung's Galaxy Buds received FDA clearance as OTC hearing aids on a similar basis.
2025–2026 — Auracast arrives in public spaces. Auracast is Bluetooth LE Audio broadcast: one audio source streams to an unlimited number of receivers at once, with low latency and better power efficiency than classic Bluetooth. Bristol Temple Meads became the first UK railway station to support it in July 2025. In January 2026, Frankfurt Airport began a pilot at gates A16 and A17, streaming gate announcements directly to compatible hearing aids and earbuds — described as the first airport in the world to do so. Vue added Auracast assistive audio at 20 cinema locations across the UK and Ireland in August 2026.
2026 — the first gene therapy for hearing loss. On April 23, 2026, the FDA approved Otarmeni (developed by Regeneron), the first gene therapy for genetic hearing loss. It is a one-time injection into the cochlea that delivers a functional OTOF gene using dual AAV vectors, intended for severe-to-profound hearing loss caused by OTOF mutations. In the CHORD phase 1/2 trial of 24 pediatric patients, 80 percent of evaluable patients showed hearing improvements by week 24, and 42 percent achieved normal hearing levels with longer follow-up.
What's next
Auracast is still early in its rollout. Major London venues — Shakespeare's Globe, the National Theatre, and the Southbank Centre — have announced plans to support Auracast by 2030, and Bluetooth LE Audio is expanding toward TVs, airports, and other public spaces.
The gene therapy pipeline does not stop at Otarmeni. Second-generation programs from Akouos (Eli Lilly), Sensorion, and Refreshgene are in trials, targeting other genetic forms of hearing loss. Restoration, rather than compensation, is becoming a plausible long-term goal.
And the hearing aid itself is converging with the wearable. Fall detection and sleep-quality tracking are already shipping in 2026 models, and heart-rate monitoring is on the horizon. The device that once sat forgotten in a drawer is becoming the sensor platform people wear all day.
The through-line of the last five years is simple: hearing technology stopped being a single expensive product and became an ecosystem — cheap enough to try, smart enough to adapt, connected enough to disappear into the background, and, at the frontier, able to treat the condition itself. For the hundreds of millions waiting for better hearing, that ecosystem is arriving right on time.
Top comments (0)